There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
New generation vaccines will increasingly comprise highly purified recombinant proteins.
Unfortunately, these antigens are often poorly immunogenic. Therefore, adjuvants will
be required to enable these proteins to become effective vaccines. Although several
novel adjuvants have recently emerged, including formulations comprising more than
one adjuvant, the approval of vaccines containing novel adjuvants has been slow, particularly
in the US. However, despite significant ongoing concerns, the necessary safety data
is now emerging to show that new generation adjuvants can be safely used in diverse
human populations. In combination with data showing the positive contributions of
the adjuvants to the immune response, this safety data should allow several vaccines
containing novel adjuvants to obtain licensure within the next few years.